摘要:
The invention relates to a composition comprising taurolidine and/or the hydrolysis products thereof and also a biodegradable (co)polymer or inorganic matrix for use as an implant for treating local infections of the skeleton and soft tissue. A lozenge and a spray solution or gargling solution likewise comprises taurolidine and/or the hydrolysis products thereof and is used in the treatment of throat inflammations, sore throats with difficulty in swallowing, inflammations of the mouth and throat area and laryngitis. A method for producing taurolidine is also disclosed.
摘要:
Compositions containing a small molecule therapeutic and an alkyl N, N-disubstituted amino acetate are disclosed. Inclusion of the alkyl N, N-disubstituted amino acetate enhances the pharmacokinetic properties of the small molecule therapeutic.
摘要:
The present invention provides a solid oral dosage form comprising olmesartan medoxomil and polyethylene glycol having a molecular weight of about 1,000 - 10,000.
摘要:
The present invention is about pharmaceutical compositions having problems of solubility and stability, the preparation method of these compositions and the medical use.
摘要:
Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF) for a period of time exceeding 3 days.
摘要:
The present invention relates to a solid pharmaceutical composition comprising at least two layers, wherein the first layer contains a non-peptide angiotensin Il receptor antagonist or a pharmaceutically acceptable salt thereof in a dissolving matrix and the second layer contains a diuretic or a pharmaceutically acceptable salt thereof. The invention also provides methods for the production of said pharmaceutical compositions.
摘要:
The invention describes new pharmaceutical compositions, their method of manufacture and use of these compositions to be administered as combination therapy for the treatment of cardiovascular and related disorders, in particular a combination of angiotensin II antagonists, lipid regulators (HMG CoA inhibitors), platelet aggregation inhibitors and diuretics.
摘要:
The present invention relates to methods for the prevention of, delay progression to or treatment of hypertension in obese patients, comprising administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor such as aliskiren or a pharmaceutically acceptable salt. The renin inhibitor may be used alone or in combination with another antihypertensive agent, in particular a diuretic such as hydrochlorothiazide.